SlideShare a Scribd company logo
1 of 1
Destabilization of the Bacterial Accumulation Associated Protein (AAP)
Through Mutation of Phenylalanine-20 to Modify Antigen Recognition
Against Biofilm Production
Sarah Albrecht, Matthew Berhe, Serena LaBounty, Elijah Lazo
Mentors: Ruying Chen, Jenny Tran; PI: Dr. Richard To
Stipends for Training Aspiring Researchers (STAR), Teach Lab, University of Washington Seattle, WA
Abstract
During the development of biofilm, bacteria produce AAP to survive
antibiotic treatment. Biofilm related infections are difficult to treat with
conventional methods due to cellular accumulation. Antibodies targeting
the AAP have been reported to reduce biofilm production. Within AAP,
each G5 repeat is coiled around a hydrophobic core and is considered an
antigenic fragment that the immune system targets. G5 presentation by
the antigen presenting cells may be improved with structural
modification. Changing the amino acid sequence may cause the
breakdown of the hydrophobic core that can destabilize the protein to
improve G5 presentation as an antigen. The hydrophobic Phenylalanine-
20 in G5 is changed into alanine by site–directed mutagenesis and the
mutated peptide sequence is inserted into the pET21a+ vector for the
peptide expression. The mutated AAP-G5 peptide will be tested with a
mice model in the future to examine immune response.
Background
• Biofilm is the leading cause of infections related to biomaterial.
S. epidermidis is the most common bacteria involved in
nosocomial infections and affects millions of people each year
[1,2].
kb
• The formation of biofilm occurs in two phases, bacteria
adhesion to a surface followed by bacterial accumulation due
to AAP secretion. [3].
• Within this AAP, there are repeated G5 domains which have
been used as vaccine to generate antibodies against AAP.
• We have mutated one G5 domain in order to increase immune
response against the formation of biofilm.
• The G5 domain has the capacity of being hydrophobic or
hydrophilic due to an excess glycine, the smallest amino acid
that has a single hydrogen side chain.
• Phenylalanine-20 is a hydrophobic amino acid.
When grouped with surrounding hydrophobic
amino acids, it creates a dense stack.
(See figure A)
• We attempted to mutate Phenylalanine-20
into alanine that is less hydrophobic.
• Due to the decrease in hydrophobicity, the mutated G5 is
expected to break down easier by antigen presenting cells,
potentially leading to a more effective transfer by MHCII to the
T cells.
pVAX
pVAX
pVAX
pET21a+
p-VAX-MutAAP
Miniprep
- Extract pVAX-AAP plasmid from cellwtAAPG5
Restriction Analysis
Mutagenesis
-Change Phenylalanie-20 to
Alanine
MutG5
XL-10 Blue
Miniprep
-Extract mutated plasmidMutAAP
DNA Sequencing
-Used the Sangers method
Polymerase Chain
Reaction (PCR)
-Amplify mutated AAP
domain
Ligation
-Splice mutated AAP domain
into pET21a+ plasmid
T7 Promoter
MutAAP
pET-MutAAP
Transform to BL21DE3 cells
for Protein Expression
Top10F’ Cells
Transformation
-Insert mutated plasmid into
XL-10 Blue cells
Methods
Acknowledgements:
This research was made possible by the NIH National Heart Lung & Blood Institute Grant #5R25HL103180-05 "UW STAR Program”. Thank you to Dr. Richard To, our lab mentor and
professor, for showing us how to conduct research and for teaching us how to work in a scientific manor. Thank you to Karlotta Rosebaugh and Teri Ward, for giving us this opportunity
to broaden our horizons. Thank you to our lab assistants Ruying Chen and Jenny Tran for educational guidance and support. Finally, thank you to all the lab participants for making this
internship an experience to remember.
References:
1. J. C. Linnes, K. Mikhova, and J. D. Bryers, “Adhesion of Staphylococcus epidermidis to biomaterials is inhibited by fibronectin and albumin.,” J. Biomed. Mater. Res. A, vol. 100, no. 8,
pp. 1990–7, Aug. 2012.
2. T. Bjarnsholt, “The role of bacterial biofilms in chronic infections.,” APMIS. Suppl., no. 136, pp. 1–51, May 2013.
3. D. Sun, M. A. Accavitti, J. D. Bryers, D. Sun, M. A. Accavitti, and J. D. Bryers, “Inhibition of Biofilm Formation by Monoclonal Antibodies against Staphylococcus epidermidis RP62A
Accumulation-Associated Protein Inhibition of Biofilm Formation by Monoclonal Antibodies against Staphylococcus epidermidis RP62A Accumulation- Associated Protein,” 2005.
Genomic DNA pVAX-AAP
ResultsResults
• Extracted and isolated the pET 21
• Restriction analysis proves pET 21 is present (Figure 1)
• pET 21 this vector was amplified and purified
~1.8 µg/mL (Figure 2)
• pVAX Mutagenesis was unsuccessful
~kanamycin resistant bacteria colony was not present in
the subsequent transformation
• Used alternative pVAX mutagenesis as a control (Figure 3)
B Region
Colony Polymerase Chain Reaction (PCR)
- Amplify the mutated pET21a+
with the inserted pVAX.
Conclusion
• The pET 21 was uncontaminated and it was confirmed the
presence of DNA with a UV spectrometry and gel purification.
• The transformation of pVAXAAP was unsuccessful and the
problem potentially occurred some point after mutagenesis.
~Mutagenesis and Transformation: Primers didn’t match
up and couldn’t make copies or could not mutate the
plasmid.
• The ligation of pET21 was successful. Future experiments are
needed to study the mutagenesis and transformation of the
pVAX. (Figure 2)
The future plan is to perform in vivo in mice with the mutated G-5
and observe the immune response. The immunization with
mutated G5 may increase the antibody production against AAP
and should hinder biofilm formation. The hope is to be able to
destroy biofilms much more efficiently to decrease nosocomial
infections.
Figure 1 Figure 3Figure 2 Figure 3

More Related Content

What's hot

Safi et al.ng.2743
Safi et al.ng.2743Safi et al.ng.2743
Safi et al.ng.2743Hassan Safi
 
Strategies for Recombinant protein production in E.coli
Strategies for Recombinant protein production in E.coliStrategies for Recombinant protein production in E.coli
Strategies for Recombinant protein production in E.coliUka Tarsadia University
 
Seminario Biologia Molecular
Seminario Biologia Molecular Seminario Biologia Molecular
Seminario Biologia Molecular camilaaceros
 
Protein engineering
Protein engineeringProtein engineering
Protein engineeringBen Mair
 
NCUR presentation 2014 - revised
NCUR presentation 2014 - revisedNCUR presentation 2014 - revised
NCUR presentation 2014 - revisedPaige Haas
 
Gene stacking and its materiality in crop improvement
Gene stacking and its materiality in crop improvementGene stacking and its materiality in crop improvement
Gene stacking and its materiality in crop improvementShamlyGupta
 
protein engineering and site directed mutagenesis
  protein engineering and site directed mutagenesis  protein engineering and site directed mutagenesis
protein engineering and site directed mutagenesisNawfal Aldujaily
 
Abiotic and biotic stress response/crosstalk
Abiotic and biotic stress response/crosstalkAbiotic and biotic stress response/crosstalk
Abiotic and biotic stress response/crosstalkSheikh Mansoor
 
Lectut btn-202-ppt-l34. applications of site-directed mutagenesis
Lectut btn-202-ppt-l34. applications of site-directed mutagenesisLectut btn-202-ppt-l34. applications of site-directed mutagenesis
Lectut btn-202-ppt-l34. applications of site-directed mutagenesisRishabh Jain
 
Prime-ome: "A molecular approach towards defense priming"
Prime-ome: "A molecular approach towards defense priming"Prime-ome: "A molecular approach towards defense priming"
Prime-ome: "A molecular approach towards defense priming"Dhanya AJ
 
systemic signal in plant defence
systemic signal in plant defencesystemic signal in plant defence
systemic signal in plant defenceManoj Yadav
 
Cloning and Expression of recombinant Protein
Cloning and Expression of recombinant ProteinCloning and Expression of recombinant Protein
Cloning and Expression of recombinant ProteinGaurav Dwivedi
 
ROLE OF JASMONIC ACID IN PLANT DEVELOPMENT &DEFENCE MECHANISM
ROLE OF JASMONIC ACID IN PLANT DEVELOPMENT &DEFENCE MECHANISMROLE OF JASMONIC ACID IN PLANT DEVELOPMENT &DEFENCE MECHANISM
ROLE OF JASMONIC ACID IN PLANT DEVELOPMENT &DEFENCE MECHANISMBHU,Varanasi, INDIA
 
Clarkson et al. Biochem J 1987
Clarkson et al. Biochem J 1987Clarkson et al. Biochem J 1987
Clarkson et al. Biochem J 1987George Clarkson
 
Development of strategies for management of infections with carbapenem resist...
Development of strategies for management of infections with carbapenem resist...Development of strategies for management of infections with carbapenem resist...
Development of strategies for management of infections with carbapenem resist...Bhoj Raj Singh
 
BIOL302L Poster(1)
BIOL302L Poster(1)BIOL302L Poster(1)
BIOL302L Poster(1)Mintong Nan
 

What's hot (20)

Safi et al.ng.2743
Safi et al.ng.2743Safi et al.ng.2743
Safi et al.ng.2743
 
Strategies for Recombinant protein production in E.coli
Strategies for Recombinant protein production in E.coliStrategies for Recombinant protein production in E.coli
Strategies for Recombinant protein production in E.coli
 
Seminario Biologia Molecular
Seminario Biologia Molecular Seminario Biologia Molecular
Seminario Biologia Molecular
 
Protein engineering
Protein engineeringProtein engineering
Protein engineering
 
NCUR presentation 2014 - revised
NCUR presentation 2014 - revisedNCUR presentation 2014 - revised
NCUR presentation 2014 - revised
 
zahid hussain ajk
zahid hussain ajkzahid hussain ajk
zahid hussain ajk
 
Gene stacking and its materiality in crop improvement
Gene stacking and its materiality in crop improvementGene stacking and its materiality in crop improvement
Gene stacking and its materiality in crop improvement
 
protein engineering and site directed mutagenesis
  protein engineering and site directed mutagenesis  protein engineering and site directed mutagenesis
protein engineering and site directed mutagenesis
 
Abiotic and biotic stress response/crosstalk
Abiotic and biotic stress response/crosstalkAbiotic and biotic stress response/crosstalk
Abiotic and biotic stress response/crosstalk
 
Lectut btn-202-ppt-l34. applications of site-directed mutagenesis
Lectut btn-202-ppt-l34. applications of site-directed mutagenesisLectut btn-202-ppt-l34. applications of site-directed mutagenesis
Lectut btn-202-ppt-l34. applications of site-directed mutagenesis
 
Prime-ome: "A molecular approach towards defense priming"
Prime-ome: "A molecular approach towards defense priming"Prime-ome: "A molecular approach towards defense priming"
Prime-ome: "A molecular approach towards defense priming"
 
2013_WCBSURC.pptx
2013_WCBSURC.pptx2013_WCBSURC.pptx
2013_WCBSURC.pptx
 
Seminario biomol
Seminario biomolSeminario biomol
Seminario biomol
 
systemic signal in plant defence
systemic signal in plant defencesystemic signal in plant defence
systemic signal in plant defence
 
Cloning and Expression of recombinant Protein
Cloning and Expression of recombinant ProteinCloning and Expression of recombinant Protein
Cloning and Expression of recombinant Protein
 
ROLE OF JASMONIC ACID IN PLANT DEVELOPMENT &DEFENCE MECHANISM
ROLE OF JASMONIC ACID IN PLANT DEVELOPMENT &DEFENCE MECHANISMROLE OF JASMONIC ACID IN PLANT DEVELOPMENT &DEFENCE MECHANISM
ROLE OF JASMONIC ACID IN PLANT DEVELOPMENT &DEFENCE MECHANISM
 
Clarkson et al. Biochem J 1987
Clarkson et al. Biochem J 1987Clarkson et al. Biochem J 1987
Clarkson et al. Biochem J 1987
 
Stress inducible promoters
Stress inducible promotersStress inducible promoters
Stress inducible promoters
 
Development of strategies for management of infections with carbapenem resist...
Development of strategies for management of infections with carbapenem resist...Development of strategies for management of infections with carbapenem resist...
Development of strategies for management of infections with carbapenem resist...
 
BIOL302L Poster(1)
BIOL302L Poster(1)BIOL302L Poster(1)
BIOL302L Poster(1)
 

Viewers also liked

Stability Of Peptides And Proteins
Stability Of Peptides And ProteinsStability Of Peptides And Proteins
Stability Of Peptides And ProteinsThilak Chandra
 
Protein and peptide drug delivery seminar-97-2003-final2
Protein and peptide drug delivery seminar-97-2003-final2Protein and peptide drug delivery seminar-97-2003-final2
Protein and peptide drug delivery seminar-97-2003-final2Pravin Chinchole
 
Protein and peptide drug delivery system
Protein and peptide drug delivery systemProtein and peptide drug delivery system
Protein and peptide drug delivery systemSagar Savale
 
protein and peptide drug delivery system
protein and peptide drug delivery system protein and peptide drug delivery system
protein and peptide drug delivery system Brajesh Kumar
 
Oral drug delivery proteins
Oral drug delivery proteinsOral drug delivery proteins
Oral drug delivery proteinsswati gadekar
 

Viewers also liked (7)

Stability Of Peptides And Proteins
Stability Of Peptides And ProteinsStability Of Peptides And Proteins
Stability Of Peptides And Proteins
 
protein stability
protein stabilityprotein stability
protein stability
 
Protein and peptide drug delivery seminar-97-2003-final2
Protein and peptide drug delivery seminar-97-2003-final2Protein and peptide drug delivery seminar-97-2003-final2
Protein and peptide drug delivery seminar-97-2003-final2
 
Protein and peptide drug delivery system
Protein and peptide drug delivery systemProtein and peptide drug delivery system
Protein and peptide drug delivery system
 
Protein and peptide d d s
Protein and peptide d d sProtein and peptide d d s
Protein and peptide d d s
 
protein and peptide drug delivery system
protein and peptide drug delivery system protein and peptide drug delivery system
protein and peptide drug delivery system
 
Oral drug delivery proteins
Oral drug delivery proteinsOral drug delivery proteins
Oral drug delivery proteins
 

Similar to AAPG5 Project 1

Beta lactamases.pptx
Beta lactamases.pptxBeta lactamases.pptx
Beta lactamases.pptxChinmoy Sahu
 
Microbiology antibiotic
Microbiology   antibioticMicrobiology   antibiotic
Microbiology antibioticMBBS IMS MSU
 
DNA Vaccine + Nanoparticles
DNA Vaccine + NanoparticlesDNA Vaccine + Nanoparticles
DNA Vaccine + NanoparticlesHamid Salari
 
Cyclic lipopeptides, folate antagonists, licosamide, polymixins
Cyclic lipopeptides, folate antagonists, licosamide, polymixinsCyclic lipopeptides, folate antagonists, licosamide, polymixins
Cyclic lipopeptides, folate antagonists, licosamide, polymixinsAreej Abu Hanieh
 
Site-Directed Mutagenesis of β-2 Microglobulin Research Symposium Poster
Site-Directed Mutagenesis of β-2 Microglobulin Research Symposium PosterSite-Directed Mutagenesis of β-2 Microglobulin Research Symposium Poster
Site-Directed Mutagenesis of β-2 Microglobulin Research Symposium PosterTyler Liang
 
Presentation-antibiotics (PP503).ppt
Presentation-antibiotics (PP503).pptPresentation-antibiotics (PP503).ppt
Presentation-antibiotics (PP503).pptRamGuha
 
Lecture 7 micro-antibiotics-mbbs
Lecture 7 micro-antibiotics-mbbsLecture 7 micro-antibiotics-mbbs
Lecture 7 micro-antibiotics-mbbsMBBS IMS MSU
 
1015893 IAS characterization poster v10, final 071415
1015893 IAS characterization poster v10, final 0714151015893 IAS characterization poster v10, final 071415
1015893 IAS characterization poster v10, final 071415Ira Dicker
 
Antimicrobial agents and mechanisms of action 2
Antimicrobial agents and mechanisms of action 2Antimicrobial agents and mechanisms of action 2
Antimicrobial agents and mechanisms of action 2Bruno Mmassy
 
Beta lactam Antibiotics .ppt
Beta lactam Antibiotics .pptBeta lactam Antibiotics .ppt
Beta lactam Antibiotics .pptMahavir Ghante
 
Glycopeptides, fluoroquinolones, aminoglycosides Drugs
Glycopeptides, fluoroquinolones, aminoglycosides DrugsGlycopeptides, fluoroquinolones, aminoglycosides Drugs
Glycopeptides, fluoroquinolones, aminoglycosides DrugsAreej Abu Hanieh
 
Presentation_defense_final_3
Presentation_defense_final_3Presentation_defense_final_3
Presentation_defense_final_3Ksenia Yakhontova
 
Antimicrobial agents and mechanisms of action 2
Antimicrobial agents and mechanisms of action 2Antimicrobial agents and mechanisms of action 2
Antimicrobial agents and mechanisms of action 2Bruno Mmassy
 
Ubiquitination of Activation-Induced Cytidine Deaminase by RNF126 2011
Ubiquitination of Activation-Induced Cytidine Deaminase by RNF126 2011Ubiquitination of Activation-Induced Cytidine Deaminase by RNF126 2011
Ubiquitination of Activation-Induced Cytidine Deaminase by RNF126 2011Chittampalli (Yasha) N. Yashaswini
 
monoclonal antibodies and engineered antibodies
monoclonal antibodies and engineered antibodiesmonoclonal antibodies and engineered antibodies
monoclonal antibodies and engineered antibodiesMunawar Ali
 
Beta lactam antibiotics
Beta lactam antibioticsBeta lactam antibiotics
Beta lactam antibioticsSmita Shukla
 
The Role Of Mir 125A And Mir 223
The Role Of Mir 125A And Mir 223The Role Of Mir 125A And Mir 223
The Role Of Mir 125A And Mir 223Jenny Richardson
 

Similar to AAPG5 Project 1 (20)

Beta lactamases.pptx
Beta lactamases.pptxBeta lactamases.pptx
Beta lactamases.pptx
 
Microbiology antibiotic
Microbiology   antibioticMicrobiology   antibiotic
Microbiology antibiotic
 
DNA Vaccine + Nanoparticles
DNA Vaccine + NanoparticlesDNA Vaccine + Nanoparticles
DNA Vaccine + Nanoparticles
 
Cyclic lipopeptides, folate antagonists, licosamide, polymixins
Cyclic lipopeptides, folate antagonists, licosamide, polymixinsCyclic lipopeptides, folate antagonists, licosamide, polymixins
Cyclic lipopeptides, folate antagonists, licosamide, polymixins
 
Site-Directed Mutagenesis of β-2 Microglobulin Research Symposium Poster
Site-Directed Mutagenesis of β-2 Microglobulin Research Symposium PosterSite-Directed Mutagenesis of β-2 Microglobulin Research Symposium Poster
Site-Directed Mutagenesis of β-2 Microglobulin Research Symposium Poster
 
Presentation-antibiotics (PP503).ppt
Presentation-antibiotics (PP503).pptPresentation-antibiotics (PP503).ppt
Presentation-antibiotics (PP503).ppt
 
Lecture 7 micro-antibiotics-mbbs
Lecture 7 micro-antibiotics-mbbsLecture 7 micro-antibiotics-mbbs
Lecture 7 micro-antibiotics-mbbs
 
1015893 IAS characterization poster v10, final 071415
1015893 IAS characterization poster v10, final 0714151015893 IAS characterization poster v10, final 071415
1015893 IAS characterization poster v10, final 071415
 
Antimicrobial agents and mechanisms of action 2
Antimicrobial agents and mechanisms of action 2Antimicrobial agents and mechanisms of action 2
Antimicrobial agents and mechanisms of action 2
 
Beta lactam Antibiotics .ppt
Beta lactam Antibiotics .pptBeta lactam Antibiotics .ppt
Beta lactam Antibiotics .ppt
 
Sortase enzyme family
Sortase enzyme familySortase enzyme family
Sortase enzyme family
 
Glycopeptides, fluoroquinolones, aminoglycosides Drugs
Glycopeptides, fluoroquinolones, aminoglycosides DrugsGlycopeptides, fluoroquinolones, aminoglycosides Drugs
Glycopeptides, fluoroquinolones, aminoglycosides Drugs
 
Presentation_defense_final_3
Presentation_defense_final_3Presentation_defense_final_3
Presentation_defense_final_3
 
Antimicrobial agents and mechanisms of action 2
Antimicrobial agents and mechanisms of action 2Antimicrobial agents and mechanisms of action 2
Antimicrobial agents and mechanisms of action 2
 
Ubiquitination of Activation-Induced Cytidine Deaminase by RNF126 2011
Ubiquitination of Activation-Induced Cytidine Deaminase by RNF126 2011Ubiquitination of Activation-Induced Cytidine Deaminase by RNF126 2011
Ubiquitination of Activation-Induced Cytidine Deaminase by RNF126 2011
 
monoclonal antibodies and engineered antibodies
monoclonal antibodies and engineered antibodiesmonoclonal antibodies and engineered antibodies
monoclonal antibodies and engineered antibodies
 
Penicillin
PenicillinPenicillin
Penicillin
 
Beta lactam antibiotics
Beta lactam antibioticsBeta lactam antibiotics
Beta lactam antibiotics
 
The Role Of Mir 125A And Mir 223
The Role Of Mir 125A And Mir 223The Role Of Mir 125A And Mir 223
The Role Of Mir 125A And Mir 223
 
Peptidomimetics
PeptidomimeticsPeptidomimetics
Peptidomimetics
 

AAPG5 Project 1

  • 1. Destabilization of the Bacterial Accumulation Associated Protein (AAP) Through Mutation of Phenylalanine-20 to Modify Antigen Recognition Against Biofilm Production Sarah Albrecht, Matthew Berhe, Serena LaBounty, Elijah Lazo Mentors: Ruying Chen, Jenny Tran; PI: Dr. Richard To Stipends for Training Aspiring Researchers (STAR), Teach Lab, University of Washington Seattle, WA Abstract During the development of biofilm, bacteria produce AAP to survive antibiotic treatment. Biofilm related infections are difficult to treat with conventional methods due to cellular accumulation. Antibodies targeting the AAP have been reported to reduce biofilm production. Within AAP, each G5 repeat is coiled around a hydrophobic core and is considered an antigenic fragment that the immune system targets. G5 presentation by the antigen presenting cells may be improved with structural modification. Changing the amino acid sequence may cause the breakdown of the hydrophobic core that can destabilize the protein to improve G5 presentation as an antigen. The hydrophobic Phenylalanine- 20 in G5 is changed into alanine by site–directed mutagenesis and the mutated peptide sequence is inserted into the pET21a+ vector for the peptide expression. The mutated AAP-G5 peptide will be tested with a mice model in the future to examine immune response. Background • Biofilm is the leading cause of infections related to biomaterial. S. epidermidis is the most common bacteria involved in nosocomial infections and affects millions of people each year [1,2]. kb • The formation of biofilm occurs in two phases, bacteria adhesion to a surface followed by bacterial accumulation due to AAP secretion. [3]. • Within this AAP, there are repeated G5 domains which have been used as vaccine to generate antibodies against AAP. • We have mutated one G5 domain in order to increase immune response against the formation of biofilm. • The G5 domain has the capacity of being hydrophobic or hydrophilic due to an excess glycine, the smallest amino acid that has a single hydrogen side chain. • Phenylalanine-20 is a hydrophobic amino acid. When grouped with surrounding hydrophobic amino acids, it creates a dense stack. (See figure A) • We attempted to mutate Phenylalanine-20 into alanine that is less hydrophobic. • Due to the decrease in hydrophobicity, the mutated G5 is expected to break down easier by antigen presenting cells, potentially leading to a more effective transfer by MHCII to the T cells. pVAX pVAX pVAX pET21a+ p-VAX-MutAAP Miniprep - Extract pVAX-AAP plasmid from cellwtAAPG5 Restriction Analysis Mutagenesis -Change Phenylalanie-20 to Alanine MutG5 XL-10 Blue Miniprep -Extract mutated plasmidMutAAP DNA Sequencing -Used the Sangers method Polymerase Chain Reaction (PCR) -Amplify mutated AAP domain Ligation -Splice mutated AAP domain into pET21a+ plasmid T7 Promoter MutAAP pET-MutAAP Transform to BL21DE3 cells for Protein Expression Top10F’ Cells Transformation -Insert mutated plasmid into XL-10 Blue cells Methods Acknowledgements: This research was made possible by the NIH National Heart Lung & Blood Institute Grant #5R25HL103180-05 "UW STAR Program”. Thank you to Dr. Richard To, our lab mentor and professor, for showing us how to conduct research and for teaching us how to work in a scientific manor. Thank you to Karlotta Rosebaugh and Teri Ward, for giving us this opportunity to broaden our horizons. Thank you to our lab assistants Ruying Chen and Jenny Tran for educational guidance and support. Finally, thank you to all the lab participants for making this internship an experience to remember. References: 1. J. C. Linnes, K. Mikhova, and J. D. Bryers, “Adhesion of Staphylococcus epidermidis to biomaterials is inhibited by fibronectin and albumin.,” J. Biomed. Mater. Res. A, vol. 100, no. 8, pp. 1990–7, Aug. 2012. 2. T. Bjarnsholt, “The role of bacterial biofilms in chronic infections.,” APMIS. Suppl., no. 136, pp. 1–51, May 2013. 3. D. Sun, M. A. Accavitti, J. D. Bryers, D. Sun, M. A. Accavitti, and J. D. Bryers, “Inhibition of Biofilm Formation by Monoclonal Antibodies against Staphylococcus epidermidis RP62A Accumulation-Associated Protein Inhibition of Biofilm Formation by Monoclonal Antibodies against Staphylococcus epidermidis RP62A Accumulation- Associated Protein,” 2005. Genomic DNA pVAX-AAP ResultsResults • Extracted and isolated the pET 21 • Restriction analysis proves pET 21 is present (Figure 1) • pET 21 this vector was amplified and purified ~1.8 µg/mL (Figure 2) • pVAX Mutagenesis was unsuccessful ~kanamycin resistant bacteria colony was not present in the subsequent transformation • Used alternative pVAX mutagenesis as a control (Figure 3) B Region Colony Polymerase Chain Reaction (PCR) - Amplify the mutated pET21a+ with the inserted pVAX. Conclusion • The pET 21 was uncontaminated and it was confirmed the presence of DNA with a UV spectrometry and gel purification. • The transformation of pVAXAAP was unsuccessful and the problem potentially occurred some point after mutagenesis. ~Mutagenesis and Transformation: Primers didn’t match up and couldn’t make copies or could not mutate the plasmid. • The ligation of pET21 was successful. Future experiments are needed to study the mutagenesis and transformation of the pVAX. (Figure 2) The future plan is to perform in vivo in mice with the mutated G-5 and observe the immune response. The immunization with mutated G5 may increase the antibody production against AAP and should hinder biofilm formation. The hope is to be able to destroy biofilms much more efficiently to decrease nosocomial infections. Figure 1 Figure 3Figure 2 Figure 3